Chembio Diagnostics Inc (CEMI) Return on Investment ROI from the fourth quarter of 2022 to fourth quarter of 2021 and for the year 2022, average high and low, overall ranking from Dec 31 2022 to Dec 31 2021 - CSIMarket
CSIMarket
 


Chembio Diagnostics Inc   (NASDAQ: CEMI)


Chembio Diagnostics Inc's ROI from its fourth quarter of 2022 to the fourth quarter of 2021 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Chembio Diagnostics Inc's ROI in the fourth quarter of 2022?
Chembio Diagnostics Inc recorded a cumulative net loss of $-23 million during 12 months ending in the fourth quarter of 2022, resulting in a negative return on investment (ROI) of -80.99%.

Within the Healthcare sector 852 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2022 from 0 to 5406.

Definition and Formula of Return on Investment



Return On Investment (Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Investment Change TTM -44.22 % -27.95 % -0.97 % -9.57 % -5.48 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 18 18 36 43 52
Return On Investment (TTM) -80.99 % -97.69 % -73.05 % -75.76 % -65.76 %
CEMI's Overall Ranking # 5406 # 0 # 0 # 0 # 0
Seq. Investment Change TTM -22.84 % -24.53 % -2.04 % -2.23 % -0.33 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -23 -36 -36 -38 -34




Return On Investment CEMI's Ranking
Within: No.
Industry # 383
Sector # 853
Overall # 5406

Return On Investment Statistics
High Average Low
7.53 %
-33.18 %
-92.56 %
(Sep 30 2013)   (Mar 31 2017)







Financial Statements
Chembio Diagnostics Inc's IV. Quarter Investments $ 18 Millions CEMI's Balance sheet
Chembio Diagnostics Inc's IV. Quarter Income $ -1 Millions Quarterly CEMI's Income Statement
CEMI's Income by Division See CEMI's Income by Division


CEMI Annual Return On Investment (Dec 31 2022)
2022
(Dec 31 2021)
2021
(Dec 31 2020)
2020
(Dec 31 2019)
2019
(Dec 31 2018)
2018
Total Investments in Millions 18 52 53 49 34
Y / Y Investment Growth -65.66 % -1.31 % 6.6 % 43.31 % 154.38 %
Net Income in Millions -23 -34 -26 -14 -8
Y / Y Net Income Growth - - - - -
Annual Return On Investment -130.78 % -65.38 % -48.57 % -27.75 % -22.87 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CEMI's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CEMI's Competitors
Subscribers only: Roi for Chembio Diagnostics Inc's Suppliers
Subscribers only: Return On Investment for CEMI's Customers

Other Ratios
CEMI's Roa CEMI's Inventory Turnover Ratio CEMI's Growth Rates CEMI's Dividend Statistics
CEMI's Profitability Ratios CEMI's Asset Turnover Ratio CEMI's Dividend Growth
CEMI's Roe CEMI's Valuation Ratios CEMI's Financial Strength Ratios CEMI's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2022, within Healthcare Sector ROI


Date modified: 2026-09-08T15:10:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.